Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34347509/

Introduction: KRAS is the most frequently mutated oncogenic driver in pancreatic, lung, and colon cancer. Recently, KRAS inhibitors in clinical use show promising activity but most responses are partial and drug resistance develops. The use of therapeutics in combination with KRAS inhibitors are expected to improve outcomes.